Literature DB >> 3666290

Structure-activity analysis of microsomal antigen/thyroid peroxidase.

Y Nakajima1, R D Howells, C Pegg, E D Jones, B R Smith.   

Abstract

The interaction between thyroid microsomal autoantibodies and thyroid microsomal antigen/thyroid peroxidase (TPO) has been studied using both intact antigen preparations and their water-soluble trypsin fragments. In an analysis of sera from 30 patients with Graves' or Hashimoto's diseases, microsomal antibodies showed similar reactivity towards trypsin fragments (with TPO activity) and intact detergent (sodium deoxycholate, DOC)-solubilized human microsomal antigen preparations (r = 0.96). This raised the possibility that both the peroxidase-active site and the major autoantigenic site(s) of microsomal antigen were present on the same trypsin fragments. Studies with porcine TPO showed that only a few sera contained microsomal antibodies which cross-reacted strongly with the porcine preparations. Further analysis was carried out by immunoprecipitation of 125I-labelled microsomal antigen followed by SDS-PAGE and autoradiography. These studies suggest that intact human microsomal antigen (a single-chain protein with Mr = 110,000) contains an intrachain loop of amino acids formed by a disulphide bridge. Trypsin treatment cleaves the antigen close to its transmembrane section and releases a water-soluble fragment (Mr = 100,000), containing the intact disulphide-linked loop of amino acids. Further trypsin action causes cleavage of the peptide bonds within the loop in some preparations. Consequently, three major water-soluble trypsin fragments (Mr = 100,000, 73,000 and 68,000) are formed all of which contain an intact disulphide bridge and have microsomal antibody binding activities. The integrity of the disulphide bridge in intact antigen/TPO preparations and their trypsin fragments is essential for autoantibody binding activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3666290     DOI: 10.1016/0303-7207(87)90187-0

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  7 in total

1.  The effect of sulphydryl reagents on the human thyroid microsomal antigen.

Authors:  A Gardas; H Domek
Journal:  J Endocrinol Invest       Date:  1988-05       Impact factor: 4.256

2.  Generation of recombinant, enzymatically active human thyroid peroxidase and its recognition by antibodies in the sera of patients with Hashimoto's thyroiditis.

Authors:  K D Kaufman; B Rapoport; P Seto; G D Chazenbalk; R P Magnusson
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

3.  Rarity of autoantibodies to a major autoantigen, thyroid peroxidase, that interact with denatured antigen or with epitopes outside the immunodominant region.

Authors:  J Guo; Y Wang; J C Jaume; B Rapoport; S M McLachlan
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

4.  Human organ-specific autoimmune disease. Molecular cloning and expression of an autoantibody gene repertoire for a major autoantigen reveals an antigenic immunodominant region and restricted immunoglobulin gene usage in the target organ.

Authors:  G D Chazenbalk; S Portolano; D Russo; J S Hutchison; B Rapoport; S McLachlan
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

5.  Recognition by recombinant autoimmune thyroid disease-derived Fab fragments of a dominant conformational epitope on human thyroid peroxidase.

Authors:  S Portolano; G D Chazenbalk; P Seto; J S Hutchison; B Rapoport; S M McLachlan
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

6.  Use of recombinant epitopes to study the heterogeneous nature of the autoantibodies against thyroid peroxidase in autoimmune thyroid disease.

Authors:  E Zanelli; M Henry; Y Malthiery
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

Review 7.  Thyroid Autoantibodies Display both "Original Antigenic Sin" and Epitope Spreading.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Front Immunol       Date:  2017-12-20       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.